| Title |
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
|
|---|---|
| Published in |
Oncotarget, November 2013
|
| DOI | 10.18632/oncotarget.1572 |
| Pubmed ID | |
| Authors |
Anastasia Wyce, Yan Degenhardt, Yuchen Bai, BaoChau Le, Susan Korenchuk, Ming-Chih Crouthamel, Charles F. McHugh, Robert Vessella, Caretha L. Creasy, Peter J. Tummino, Olena Barbash |
| Abstract |
BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation. Small molecule BET inhibitors prevent binding of BET proteins to acetylated histones and inhibit transcriptional activation of BET target genes. BET inhibitors attenuate cell growth and survival in several hematologic cancer models, partially through the down-regulation of the critical oncogene, MYC. We hypothesized that BET inhibitors will regulate MYC expression in solid tumors that frequently over-express MYC. Here we describe the effects of the highly specific BET inhibitor, I-BET762, on MYC expression in prostate cancer models. I-BET762 potently reduced MYC expression in prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo. Our data suggests that I-BET762 effects are partially driven by MYC down-regulation and underlines the critical importance of additional mechanisms of I-BET762 induced phenotypes. |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Denmark | 1 | <1% |
| Unknown | 111 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 27 | 24% |
| Student > Ph. D. Student | 20 | 18% |
| Student > Master | 16 | 14% |
| Student > Bachelor | 10 | 9% |
| Student > Postgraduate | 5 | 4% |
| Other | 13 | 12% |
| Unknown | 22 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 24 | 21% |
| Biochemistry, Genetics and Molecular Biology | 18 | 16% |
| Chemistry | 16 | 14% |
| Medicine and Dentistry | 14 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Other | 7 | 6% |
| Unknown | 26 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#2,382,656
of 23,549,388 outputs
Outputs from Oncotarget
#981
of 14,431 outputs
Outputs of similar age
#27,874
of 305,903 outputs
Outputs of similar age from Oncotarget
#4
of 46 outputs
Altmetric has tracked 23,549,388 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,431 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,903 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.